Letter by Koh Regarding Article, “Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey)”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Bress et al1 estimated the deaths prevented and excess serious adverse events incurred if the SPRINT (Systolic Blood Pressure Intervention Trial) intensive systolic blood pressure (SBP) treatment goal were implemented in all eligible US adults and observed that, if fully implemented in eligible US adults, intensive SBP treatment could prevent ≈107 500 deaths per year; however, a consequence of this treatment strategy could be an increase in serious adverse events.
The best therapeutic target of SBP has been …